Arcutis Biotherapeutics (ARQT) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 116.7% versus a loss of 10.6%. Over five years, TNGX leads with a +110.0% price change compared with +58.1% for ARQT. Tango Therapeutics is the larger company by market cap ($3.68 billion vs $3.33 billion), about 1.1 times the size, while Arcutis Biotherapeutics is growing revenue faster (+91.3% vs +48.3%).
Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -162.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | TNGX |
|---|---|---|
| Share price | $26.36 | $21.73 |
| Market cap | $3.33B | $3.68B |
| 1-day change | -2.98% | -4.32% |
| YTD return | -9.23% | +145.26% |
| 1-year return | -10.61% | +116.65% |
| 5-year return | +58.13% | +109.95% |
| P/E ratio (TTM) | 119.82 | — |
| Forward P/E | 24.09 | — |
| EPS (TTM) | $0.22 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $62.38M |
| Revenue growth (YoY) | +91.34% | +48.29% |
| Net income (latest FY) | $-16.14M | $-101.59M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | -178.39% |
| Net margin | -4.29% | -162.85% |
| 52-week high | $34.80 | $34.39 |
| 52-week low | $19.30 | $8.30 |
| Distance from 52-week high | -24.25% | -36.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +53.19% | +116.29% |
| Average volume | 2.58M | 3.41M |
| Shares outstanding | 126.46M | 169.46M |
| Employees | 354 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed ARQT by 127.3 percentage points over the past year.
- Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -162.9 cents for Tango Therapeutics.
- Arcutis Biotherapeutics grew revenue faster in its latest fiscal year (+91.34% vs +48.29%).
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
ARQT vs TNGX FAQ
Which is bigger, Arcutis Biotherapeutics or Tango Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.68B compared with $3.33B for Arcutis Biotherapeutics (ARQT).
Which stock has performed better over the past year, ARQT or TNGX?
TNGX returned +116.65% over the past 12 months, compared with -10.61% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.